Clinical Trials Logo

Guillain-Barre Syndrome clinical trials

View clinical trials related to Guillain-Barre Syndrome.

Filter by:

NCT ID: NCT06334796 Completed - Stroke Clinical Trials

Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology

AIDEN
Start date: October 1, 2023
Phase: Early Phase 1
Study type: Interventional

This study examines the use of an AI-powered virtual assistant for quickly identifying and handling neurological emergencies, particularly in places with limited medical resources. The research aimed to check if this AI tool is safe and accurate enough to move on to more advanced testing stages. In a first-of-its-kind trial, the virtual assistant was tested with patients having urgent neurological issues. Neurologists first reviewed the AI's recommendations using clinical records and then assessed its performance directly with patients. The findings were as follows: neurologists agreed with the AI's decisions nearly all the time, and the AI outperformed earlier versions of Chat GPT in every tested aspect. Patients and doctors found the AI to be highly effective, rating it as excellent or very good in most cases. This suggests the AI could significantly enhance how quickly and accurately neurological emergencies are dealt with, although further trials are needed before it can be widely used.

NCT ID: NCT06300359 Not yet recruiting - Clinical trials for Guillain-Barre Syndrome

Prognostic Indicators of Gullian-Barre Syndrome

Start date: March 2024
Phase:
Study type: Observational

Prognostic indicators of Gullian-Barre syndrome and the predictive factors associated with worse prognosis in the Guillain-Barré syndrome (GBS), which can be helpful to fully evaluate the disease progression and provide proper treatments.

NCT ID: NCT06200454 Not yet recruiting - Clinical trials for Guillain-Barre Syndrome

Predictive Value of Neuromuscular Ultrasound of Cranial Nerves in Guillain-Barré Syndrome

Start date: January 8, 2024
Phase:
Study type: Observational

1. Sensitivity and specificity of cranial neuromuscular US to detect the prognosis of Guillain Barre Syndrome 2. Correlation of US values with motor, respiratory and autonomic complications of Guillain Barre Syndrome

NCT ID: NCT06167239 Recruiting - Clinical trials for Guillain-Barre Syndrome

Ventilator Trigger Sensitivity Adjustment Versus Threshold Inspiratory Muscle Training on Arterial Blood Gases

Start date: December 2, 2023
Phase: N/A
Study type: Interventional

The aim of the current study is to compare the effect of ventilator trigger sensitivity adjustment versus threshold inspiratory muscle training on arterial blood gases in mechanically ventilated patients.

NCT ID: NCT06041451 Recruiting - Clinical trials for Guillain-Barre Syndrome

Early and Late Prognosis in Patients With Guillain-Barre Syndrome

Start date: January 2, 2013
Phase: Phase 4
Study type: Interventional

The goal of this observational study is to explore significant indicators to predict the early prognosis and late prognosis in patients with Guillain-Barre syndrome.

NCT ID: NCT06032741 Recruiting - Clinical trials for Guillain-Barre Syndrome

Prognosis in Patients With Guillain-Barre Syndrome

Start date: January 2, 2013
Phase:
Study type: Observational

The goal of this observational study is to explore significant indicators to predict the early prognosis and late prognosis in patients with Guillain-Barre syndrome.

NCT ID: NCT05945784 Completed - Multiple Sclerosis Clinical Trials

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

Start date: July 21, 2023
Phase:
Study type: Observational

The purpose of this study is to investigate the accessibility of beauty products for individuals with upper extremity disabilities. By examining various factors such as packaging design, product applicators, and ease of use, this research aims to identify barriers faced by individuals with upper extremity disabilities or visual deficits when using beauty products. The study seeks to provide insights and recommendations for improving the accessibility of beauty products, ultimately promoting inclusivity and enhancing the overall beauty experience for individuals with disabilities.

NCT ID: NCT05940922 Not yet recruiting - Clinical trials for Guillain-Barre Syndrome

RWE-based Treatment Patterns and Outcomes in CIDP

Start date: August 17, 2023
Phase:
Study type: Observational

To describe the demographics, clinical characteristics, treatment patterns and clinical outcomes of chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), and heredofamilial amyloidosis (hATTR) adult patients at a single U.K. centre.

NCT ID: NCT05701189 Not yet recruiting - Clinical trials for Guillain-Barre Syndrome

Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

Start date: May 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and effectiveness of Efgartigimod in patients with Guillain-Barre syndrome (GBS). The main questions it aims to answer are: - Is Efgartigimod a safe treatment option for GBS patients? - Does treatment with Efgartigimod improve patient outcomes? In addition to standard-of-care procedures and assessments, participants will: - Undergo seven blood draws during hospitalization and in four follow-up study visits to evaluate the concentration of neurofilament light chain, a protein that is elevated in patients with Guillain-Barré syndrome. The presence of neurofilament light chain is believed to be indicative of damage to the nervous system, with higher levels resulting from greater damage. - Complete the Columbia Suicide Severity Rating Scale (C-SSRS) to monitor any suicidal ideation or behaviors during the course of the study.

NCT ID: NCT05630313 Recruiting - Clinical trials for Guillain-Barre Syndrome

Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil

Start date: October 4, 2022
Phase:
Study type: Observational

This protocol proposes to investigate genetic factors that may be involved in the pathogenesis of adverse events of interest with selected covid-19 vaccines: vaccine-induced immune thrombotic thrombocytopenia, and neurological adverse events, such as Guillain-Barré syndrome, acute disseminated encephalomyelitis and transverse myelitis, with the intention of identifying useful biomarkers in identifying people at higher risk, thus reducing the occurrence of these serious adverse events (SAE).